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Objectives This study sought to compare the long-term effects of drug-eluting stent (DES) com-
pared with bare-metal stent (BMS) implantation in patients with ST-segment elevation myocardial
infarction (STEMI) undergoing primary percutaneous coronary intervention.
Background The randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial
Infarction) trial evaluated the outcome after DES compared with BMS implantation in patients with
STEMI undergoing primary percutaneous coronary intervention.
Methods Patients with a high-grade stenosis/occlusion of a native coronary artery presenting with
symptoms 12 h and ST-segment elevation were enrolled after giving informed consent. Patients
were randomly assigned to receive a DES or a BMS in the infarct-related lesion. Patients were followed
for at least 5 years, and clinical endpoints were evaluated from population registries and hospital charts.
The main endpoint was the occurrence of the ﬁrst major adverse cardiac event (MACE), deﬁned as car-
diac death, nonfatal recurrent myocardial infarction, and target lesion revascularization.
Results Complete clinical status was available in 623 patients (99.5%) at 5 years follow-up. The com-
bined MACE rate was insigniﬁcantly lower in the DES group (16.9% vs. 23%), mainly driven by a lower
need of repeat revascularization (p  0.07). Whereas the number of deaths from all causes tended to be
higher in the DES group (16.3% vs. 12.1%, p  0.17), cardiac mortality was signiﬁcantly higher (7.7% vs.
3.2%, p  0.02). The 5-year stent thrombosis rates were generally low and similar between the DES and
the BMS groups. No cardiac deaths occurring within 1 month could be clearly ascribed to stent throm-
bosis, whereas stent thrombosis was involved in 78% of later-occurring deaths.
Conclusions The 5-year MACE rate was insigniﬁcantly different, but the cardiac mortality was higher
after DES versus BMS implantation in patients with STEMI. Stent thrombosis was the main cause of late
cardiac deaths. (J Am Coll Cardiol Intv 2013;6:548–553) © 2013 by the American College of Cardiology
Foundation
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549Primary percutaneous coronary intervention (PCI) reduces
death and recurrent myocardial infarction compared with
fibrinolysis in patients with ST-segment elevation myocar-
dial infarction (STEMI) (1,2). Drug-eluting stents (DES)
decrease the risk of restenosis and the need for target vessel
revascularization (TVR) compared with bare-metal stents
(BMS) (3,4) but at higher risk of late stent thrombosis
(5–8), especially in patients with acute coronary syndromes
(9,10). Two recent meta-analyses including data from 15
and 11 randomized controlled trials, respectively, have
evaluated the safety and efficacy of early generation DES
compared with bare-metal stents in patients undergoing
primary PCI (11,12). Both analyses found an expected,
significant reduction in TVR among patients treated with
DES and a nonsignificant trend toward a reduced mortality
even beyond 1 year of follow-up. Both analyses reported an
increased rate of late (1 year) stent thrombosis in the DES
roup. The DEDICATION (Drug Elution and Distal Pro-
ection in Acute Myocardial Infarction) trial evaluated how
mplantation of DES compared with BMS affects the outcome
n 626 patients with STEMI undergoing primary PCI. We
ave previously reported a reduced need for repeat revascular-
zation at 8 months and 3 years in the DES group (13,14). The
resent study reports complete 5-year clinical follow-up data.
ethods
Study design and patient population. Patients with a high-
grade stenosis/occlusion of a native coronary artery present-
ing with symptoms 12 h and ST-segment elevation 0.2
mV in 2 contiguous leads were enrolled after giving
informed consent.
PCI procedure and medication. All patients were treated
with aspirin, clopidogrel, unfractionated heparin, and if no
contraindication, a glycoprotein IIb/IIIa receptor blocker.
Patients were randomly assigned in a 2  2 design to
treatment with or without distal protection and to receive a
DES or a BMS in the infarct-related lesion. Lifelong
aspirin, 75 mg daily, and 12 months of clopidogrel, 75 mg
daily, were prescribed after initial treatment.
Clinical outcome follow-up. Patients were followed for at
least 5 years, and clinical endpoints were evaluated from
Danish population registries and hospital charts.
Study endpoints and deﬁnitions. The main endpoint was
he occurrence of major adverse cardiac events (MACE),
efined as cardiac death, nonfatal recurrent myocardial
nfarction, and target lesion revascularization (TLR). The
ndpoint adjudicators were blinded to the initial treatment
trategy unless angiographic review of the index procedure
as necessary to decide whether TVR or TLR was present.
A myocardial infarction occurring during follow-up was
efined as an increase above the upper normal limit of
reatine kinase-myocardial band or troponins in the pres-
nce of relevant symptoms of an acute coronary syndrome15). Stroke was defined as the development of disabling
eurological symptoms and objective findings lasting at least
4 h. TLR was defined as revascularization of the target
esion in the presence of recurrent angina, and TVR was
efined as revascularization anywhere in the index vessel.
tent thromboses were categorized according to the Aca-
emic Research Consortium definitions (16).
Statistical analysis. In order to detect a 50% reduction in
ACE (power 80%, type 1 error 5%), 600 patients had to
e included in the trial. Categorical variables were compared
sing the chi-square or Fisher exact test, and continuous
ariables were compared using the Mann-Whitney U test
nd the Student t test. The Kaplan-Meier method was used
o create survival estimates, and the log-rank test was used
or their comparison. Patients were censored at the time of
ast follow-up. The comparisons were unadjusted for other
ovariates except for randomization to distal protection.
nteraction analyses were performed by Cox proportional
azards models. All p values were 2-sided.
esults
Baseline demographics and pro-
cedural results. Of the included
26 patients, 313 received a
ES (46% sirolimus-eluting
tents, 41% paclitaxel-eluting
tents, and 13% zotarolimus-
luting stents), and 313 received
BMS (38% cobalt alloy, 62%
tainless steel). Baseline charac-
eristics of patients and lesion
re described in Table 1.
Clinical events. Patients were
followed up for a median of
2,095 days (maximum 2,493 days). Complete clinical events
data were available in 623 patients. Three patients were lost
to follow-up between 3- and 5-year follow-up due to
emigration.
The 5-year clinical outcomes are depicted in Figure 1,
and the clinical events in Table 2. The primary study
reported endpoints at 8 months follow-up, and these data
are repeated in the table. At 5 years, the combined MACE
rate tended to be lower in the DES group (p  0.07),
mainly driven by a higher need for repeat revascularization
in the BMS group. Death rates were numerically higher in
the DES group (51 vs. 38 events, p  0.17), with a
significant difference in cardiac deaths (24 vs. 10 events,
p 0.02) (Fig. 2). As previously reported, 13 patients in the
DES group versus 5 patients in the BMS group suffered a cardiac
death within 8 months after the index procedure, mainly due to
progressive heart failure or malignant arrhythmias.
Stroke rates were low at 5 years (4.2% vs. 3.2%, p 0.67,
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
MACE  major adverse
cardiac event(s)
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
TLR  target lesion
revascularization
TVR  target vessel
revascularizationdata not shown). Times to events are illustrated by the
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550Kaplan-Meier method and were compared by the log-rank
test, unadjusted for other covariates except for distal pro-
tection (cardiac mortality, p  0.77 for interaction). No
interaction was found between the use of distal protection
and the type of stent implanted.
Stent thrombosis. The occurrence of stent thrombosis is
reported in Table 3. In general, 5-year stent thrombosis
rates were low and similar in the DES and the BMS groups
(5.4%). Numerically, more definite stent thromboses were
seen in the BMS group (3.8% vs. 1.6%, p  0.14), and very
late stent thrombosis occurred in 3.2% of the DES group
and in 2.9% of the BMS group (p  NS). Three patients
Figure 1. MACE During 5 Years of Follow-Up
The primary endpoints of major adverse cardiac events (MACE) during 5 years
metal stents (BMS) (orange bars). *MACE  cardiac death, MI and TRL; MI 
Table 1. Baseline Characteristics of Patients and Lesions
DES
(n  313)
BMS
(n  313)
p
Value
Age, yrs 62 12 63 12 0.41
Men 73 74 0.93
Diabetes mellitus 9.3 11.5 0.43
Hypertension 32 34 0.67
Hyperlipidemia 19 21 0.54
Smoker 53 55 0.88
Previous myocardial infarction 6.1 7.0 0.20
Symptom onset to balloon, min (median) 222 225 0.66
Multivessel disease 35 40 0.44
Infarct-related artery LAD/CX/RCA 40/13/47 43/12/45 0.59
Baseline TIMI ﬂow grade 0–1 65 70 0.27
Values are meanSD or %, except as noted.
BMS  bare-metal stent; CX  circumflex artery; DES  drug-eluting stent; LAD  left anterior
descending coronary artery; RCA  right coronary artery; TIMI  Thrombolysis In Myocardial
Infarction.revascularization.ith a DES died of progressive heart failure, one after
dmittance for late definite stent thrombosis, whereas 7
atients survived a definite stent thrombosis in a BMS.
one of the early cardiac deaths were clearly related to a
tent thrombosis, whereas 14 of 18 (78%) occurring after 1
onth could be ascribed to a stent thrombosis.
iscussion
The higher rate of MACE in patients treated with BMS
compared with those treated with DES during primary PCI
described in earlier reports seems to vanish with time. In
this randomized study, overall MACE rates after 5 years
were insignificantly higher among patients who had re-
ceived BMS, and the tendency towards a difference was
mainly driven by an increased revascularization rate in the
BMS group during the early months after inclusion in the trial.
According to its primary endpoint, the DEDICATION trial
included a per-protocol angiographic follow-up at 8 months
that could have influenced the decision to perform revascu-
larization at that time (17–19). This could at least partly
explain the finding that the 8 months TVR rates in the
present study were higher than the 1-year TVR rates
reported in a recent meta-analysis to which the DEDICA-
TION trial also provided data (11). By contrast, revascular-
ization rates beyond 8 months and up to 5 years of
follow-up were low and not statistically significant between
the 2 groups. There were no study-related angiographic
controls during that time, so repeat revascularizations were
entirely driven by clinical symptoms. Mortality, and in
particular cardiac mortality, was significantly higher in the
low-up among patients with drug-eluting stents (DES) (green bars) or bare-
rdial infarction; TLR  target lesion revascularization; TVR  target vesselof fol
myoca
Orange lines  BMS. Abbreviations as in Figure 1.
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551DES group at 5 years follow-up, a trend that was already
present when the 8 months and 3 years results were reported
(13,14). The occurrence of very late stent thrombosis was
low and similar in the 2 groups, but stent thrombosis,
especially definite stent thrombosis, was more often associ-
ated with cardiac death in the DES group.
All-cause and cardiac mortality among our patients who
had a DES implanted were similar to those reported in the
recent meta-analysis, whereas the cardiac mortality among
the BMS patients in the present study was considerably
lower (11). Another recent meta-analysis by De Luca et al.
(12) describes a similar pattern of reduced long-term rates of
TVR and MACE in the DES group. However, patients
who have a DES implanted have a higher risk of both
reinfarction and very late stent thrombosis. Small differences
in the demographic patient data could be responsible for these
observed discrepancies. Patients enrolled in the DEDICA-
TION trial were on average 2 years older; the presence of
diabetes, hypertension, and hypercholesterolemia was lower
compared with the patients in the meta-analysis; and the
symptom onset-to-balloon duration was 30 min shorter in the
DEDICATION trial. The 3-year cardiac mortality rate was
6.8% in patients who had a BMS implanted in the meta-
Table 2. Clinical Outcomes
DES
(n  313)
BMS
(n  313) p Value
Events from 0 to 8 months
MACE* 28 (8.9) 45 (14.4) 0.05
Death 16 (5.1) 8 (2.6) 0.14
Cardiac death 13 (4.2) 5 (1.6) 0.09
MI 5 (1.6) 8 (2.6) 0.42
MI in infarct related artery 3 (1.0) 6 (1.9) 0.51
Target vessel revascularization 20 (6.4) 50 (16.0) 0.001
Target lesion revascularization 16 (5.1) 41 (13.1) 0.001
Events from 8 months to 5 years
MACE 24 (7.7) 25 (8.0) 1.00
Death 35 (11.2) 30 (9.6) 0.60
Cardiac death 11 (3.5) 5 (1.6) 0.20
MI 12 (3.8) 15 (4.8) 0.70
Target vessel revascularization 13 (4.2) 16 (5.1) 0.70
Target lesion revascularization 5 (1.6) 11 (3.5) 0.20
Events from 0 months to 5 years
MACE 53 (16.9) 72 (23.0) 0.07
Death 51 (16.3) 38 (12.1) 0.17
Cardiac death 24 (7.7) 10 (3.2) 0.02
MI 17 (5.4) 23 (7.3) 0.41
Target vessel revascularization 33 (10.5) 64 (20.4) 0.001
Target lesion revascularization 21 (6.7) 52 (16.6) 0.001
Values are n (%). *MACE at 8monthswas originally reported as the composite of cardiac death,MI
in the infarction-related artery, and target lesion revascularization (13). At 5 years, all MIs were
included as MACE.
MACEmajor adverse cardiac event(s); MImyocardial infarction; other abbreviations as in
Table 1.analysis, a level that is considerably higher than in theFigure 2. Kaplan-Meier Estimates of Survival and Freedom From MACE
Kaplan-Meier estimates of survival free of (A) MACE, (B) total mortality, and
(C) cardiac mortality among patients with DES or BMS. Green lines  DES,
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552DEDICATION population (1.9% at 3 years, 3.2% at 5
years). The HORIZONS-AMI (Harmonizing Outcomes
With Revascularization and Stents in Acute Myocardial
Infarction) trial is the largest randomized trial to date
investigating BMS versus DES in STEMI, comparing
paclitaxel-eluting stents with BMS in 3,006 patients under-
going primary PCI for STEMI (20). The combined
MACE rate was reduced in the paclitaxel group, entirely
driven by a lower rate of both TLR and TVR, whereas there
were no differences in mortality or reinfarctions in the 2
groups. Mortality in the HORIZONS-AMI trial is gener-
ally considered very low, with a 3.8% cardiac mortality in the
BMS group. For comparison, the cardiac mortality in
patients treated with BMS in the present study was 1.9% at
3 years and 3.2% at 5-year follow-up. Differences in
outcome among the trials can probably be explained in part
by a different patient selection. Compared with the
HORIZONS-AMI population, the DEDICATION pa-
tients were 3 years older and had a higher frequency of
Thrombolysis In Myocardial Infarction (TIMI) flow grade
0 and 1 in the infarct-related artery at presentation. By
contrast, the DEDICATION population had less diabetes,
hypertension, and hyperlipidemia. Symptom onset-to-
balloon durations were identical in the 2 studies. In
HORIZONS-AMI, only 64% of the BMS patients were on
thienopyridine treatment at 1-year follow-up, whereas
clopidogrel was prescribed for 12 months in both stent
groups in the DEDICATION trial. However, we did not
record the medical compliance data of our patients. Thus,
the lower mortality in the BMS group is difficult to explain
by differences in baseline and procedure-related data, but
prolonged thienopyridine treatment could play a role.
GRACE (Global Registry of Acute Coronary Events)
reported registry data on 5,093 patients treated with either
Table 3. Stent Thrombosis
DES
(n  313)
BMS
(n  313) p Value
Any stent thrombosis 17 (5.4) 17 (5.4) 1.0
Acute (24 h) 1 1
Subacute (1–30 days) 4 4
Late (30 days to 1 year) 2 3
Very late (1 year) 10 9
Deﬁnite stent thrombosis 5 (1.6) 12 (3.8) 0.14
Acute (24 h) 1 1
Subacute (1–30 days) 0 4
Late (30 days to 1 year) 2 2
Very late (1 year) 2 5
Probable stent thrombosis 4 0
Possible stent thrombosis 8 5
Values are n (%).
Abbreviations as in Table 2.DES or BMS after STEMI (21). Unadjusted 2-year mor-tality was similar among the 2 groups, with a trend toward
a higher late mortality in the DES group. It should be
stressed that comparisons generated from this registry report
necessitated propensity analyses to adjust for differences in
baseline characteristics among patients receiving DES and
BMS. Still, a higher post-discharge mortality rate was seen
in the DES group compared with the BMS group after
these adjustments, which is in accordance with the findings
of our randomized study, although it was not powered to
detect differences in mortality.
Study limitations. Stent thrombosis occurring in the early
hase of an acute coronary syndrome unrelated to mechan-
cal problems during stent implantation is closely related to
ncreased platelet activation. Patients undergoing PCI due
o acute coronary syndromes are thus at higher risk for stent
hrombosis when compared with patients undergoing PCI
or stable coronary artery disease. Therefore, late and very
ate stent thrombosis have been a matter of concern in both
andomized trials and registries of patients with STEMI
reated with primary PCI (12,22–24), even though the risk
eems to be lower with the newer-generation DES (7,25).
n the present study, we did not find an increased risk of late
tent thrombosis in the DES group, and only 2 patients had
very late (1 year) definite stent thrombosis compared
ith 5 patients treated with BMS. Overall, the definite stent
hrombosis rates at 5 years were lower in the DES group
ompared with previous reported data (11).
onclusions
Implantation of a DES in patients undergoing primary PCI
for STEMI was associated with a higher 5-year cardiac
mortality that can only partially be explained by an increased
occurrence of very late stent thrombosis. In the present
study, cardiac mortality among patients treated with BMS
was considerably lower than previously reported. Stent
thrombosis was the main cause of late cardiac deaths.
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